Pressmeddelanden från Dancann Pharma

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

DanCann Pharma A/S: No warrants exercised in extraordinary exercise period in connection with delisting 08 jan 09:10

Spotlight Stock Market has approved DanCann Pharma A/S’ application for a voluntary delisting 07 jan 12:00

DanCann Pharma A/S has today applied for a voluntary delisting from Spotlight Stock Market 06 jan 13:00

DanCann Pharma A/S: Chairman’s New Year Update 29 dec 2025 08:00

DanCann Pharma A/S: Extraordinary exercise period for warrants commences today as a result application for delisting 17 nov 2025 17:01

DanCann Pharma A/S Completes Sale of CannGros ApS to StenoCare A/S through Equity Transaction 27 okt 2025 18:00

DanCann Pharma A/S delivers Q3 2025 Highlights – Leadership Transition, Strategic Progress, and Path Toward Delisting 21 okt 2025 10:00

Minutes of Extraordinary General Meeting held in DanCann Pharma A/S 06 okt 2025 18:05

DanCann Pharma A/S: Chairman’s Letter to the Shareholders - CEO Transition and Voluntary Delisting 06 okt 2025 18:01

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S 06 okt 2025 18:00

DanCann Pharma A/S has resolved to apply for delisting from Spotlight Stock Market, subject to approval by the general meeting 25 aug 2025 19:00

DanCann Pharma A/S: Delivers Q2-2025 Highlights 09 jul 2025 22:15

DanCann Pharma A/S shares supplementary details of the obtained bridge loan 09 jul 2025 11:00

DanCann Pharma A/S signs a conditional sales agreement for the sale of manufacturing site (BP1), secures bridge financing, and launches new strategy, Maturity2028 23 maj 2025 17:05

DanCann Pharma A/S: Præsenterer højdepunkter fra 1. kvartal 2025 – Udvider receptportefølje (Rx) og forbereder indtræden på markedet for håndkøbsprodukter (OTC)23 maj 2025 17:05

DanCann Pharma A/S: Delivers Q1-2025 Highlights – Expands Prescription (Rx) Portfolio, Eyes Consumer Health Market Entry (OTC)19 maj 2025 08:30

DanCann Pharma A/S: Receives Regulatory Approval for Bedrolite® and Bedrobinol® from the Danish Medicines Agency under the Danish Pilot Programme 25 apr 2025 08:45

DanCann Pharma A/S: Adoption of Permanent Medicinal Cannabis Legislation in Denmark Completed 24 apr 2025 11:30

DanCann Pharma A/S: Updated Financial Calendar for the Remainder of 2025 24 apr 2025 11:15

DANCANN PHARMA A/S: MINUTES OF ANNUAL GENERAL MEETING 04 apr 2025 17:50

DanCann Pharma A/S: Notice of Annual General Meeting in DanCann Pharma A/S 04 apr 2025 17:45

DanCann Pharma A/S Releases 2024 Annual Report Highlighting Growth and Operational Efficiency 27 mar 2025 20:00

DanCann Pharma A/S: Postponement of release of annual report 2024 and AGM 2025 13 mar 2025 13:00

DanCann Pharma A/S forges cutting edge alliance with Tetra Pharm Technologies ApS 18 feb 2025 14:15

DanCann Pharma A/S: Completion of reverse share split and redemption of shares 17 feb 2025 08:15

DanCann Pharma A/S Publishes Its Consultation Response (“Høringssvar”) to the New Legislation on Medicinal Cannabis in Denmark 17 feb 2025 08:00

DanCann Pharma A/S: Releases Q4-2024 report – Revenue (NET) up by 27.8% YoY and EBITDA up by 63.8% YoY 21 jan 2025 17:45

DanCann Pharma A/S: Notice of redemption of shares in connection with reverse share split in the ratio 1,000:1 21 jan 2025 17:30

DanCann Pharma A/S: Minutes of Extraordinary General Meeting 06 jan 2025 08:30

DanCann Pharma A/S: Notice of proposal to Consolidate Shares in DanCann Pharma A/S 06 jan 2025 08:00

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S 10 dec 2024 14:15

DanCann Pharma A/S: DanCann Pharma Announces Outcome of Directed Issues to Board and Management 10 dec 2024 14:00

DanCann Pharma A/S: Minutes of Extraordinary General Meeting 29 nov 2024 08:00

DanCann Pharma A/S: Agreement Reached on Permanent Medicinal Cannabis Scheme in Denmark 25 nov 2024 10:20

DanCann Pharma A/S Recommends Experienced Politician and Senior Government Official to Join the Board of Directors 25 nov 2024 10:15

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S 25 nov 2024 08:00

DanCann Pharma A/S: The Board of Directors has resolved on directed share issues of DKK 4.5 million and proposal of directed share issues of DKK 0.4 million 22 nov 2024 17:30

DanCann Pharma A/S Publishes Q3-2024 Report: Steady Growth in Medicinal Cannabis Prescriptions Signals Promising Future for Patients 19 nov 2024 09:30

DanCann Pharma A/S: The Danish Government Proposes Permanent Scheme for Prescription-Based Medicinal Cannabis for Danish Patients 05 nov 2024 17:30

DanCann Pharma A/S: Capital reduction in DanCann Pharma A/S is completed 07 okt 2024 12:30

Minutes of extraordinary general meeting 24 sep 2024 16:00

DanCann Pharma A/S: Calls for an Extraordinary General Meeting regarding New Authorizations and Reduction of Share Capital in Preparation for Reverse Stock Split 20 sep 2024 18:00

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S 18 sep 2024 12:00

DanCann Pharma A/S: Number of Reported Suspected Adverse Reactions Drops by Two-Thirds in 2023 Despite 72% Growth in the Medicinal Cannabis Pilot Programme 14 aug 2024 08:15

DanCann Pharma A/S: Quarterly CEO Reflection 14 aug 2024 08:00

DanCann Pharma A/S Publishes Q2-2024 Report: Record Revenue and First-Ever Positive EBITDA 03 jul 2024 08:00

DanCann Pharma A/S announces last day for trading in temporary shares 27 jun 2024 18:45

DanCann Pharma A/S announces outcome of the Rights Issue 19 jun 2024 12:00

DanCann Pharma A/S: Last day of subscription of shares in the ongoing Rights Issue is 20 June 2024 on Nordnet Bank and Avanza Bank 18 jun 2024 13:00

DanCann Pharma A/S: Solid growth in the Rx portfolio 14 jun 2024 09:00

DanCann Pharma A/S: Germany trends – prescriptions for medicinal cannabis positively influenced by new legalization 12 jun 2024 09:00

DanCann Pharma A/S: Submits applications for FLS03 and FLS04 to expand portfolio 11 jun 2024 08:00

DanCann Pharma A/S: The subscription period of DanCann Pharma’s Rights Issue begins today 01 jun 2024 19:30

DanCann Pharma A/S: Publishes Q1-2024 Report 30 maj 2024 12:15

DanCann Pharma A/S: Minutes OF ANNUAL GENERAL MEETING 24 maj 2024 10:15

DanCann Pharma A/S: The Board of Directors has resolved on a partially (48.88 percent) secured Rights Issue of approximately DKK 18.33 million and publishes memorandum 16 maj 2024 20:30

DanCann Pharma A/S: Capital reduction completed 15 maj 2024 22:15

NOTICE OF ANNUAL GENERAL MEETING 2024 IN DANCANN PHARMA A/S 15 maj 2024 22:00

DanCann Pharma A/S Publishes Its Annual Report for 2023: A Year of Strategic Review and Future Focus on Capital Efficiency and Profitability 15 maj 2024 18:00

DanCann Pharma A/S: Updated time plan and material terms of the rights issue 17 apr 2024 12:00

DanCann Pharma A/S: MINUTES OF EXTRAORDINARY GENERAL MEETING 02 apr 2024 22:30

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S 30 mar 2024 10:15

Correction: DanCann Pharma A/S intends to initiate and complete a partly secured rights issue of up to DKK 18.5 million to restructure, strengthen and secure a debt-free capital structure 29 mar 2024 13:00

DanCann Pharma A/S intends to initiate and complete a partly secured rights issue of up to DKK 18.5 million to restructure, strengthen and secure a debt-free capital structure 28 feb 2024 10:30

DanCann Pharma A/S: Germany makes historic move towards cannabis reclassification and legalization 28 feb 2024 08:30

DanCann Pharma A/S Reports Fourth Quarter and Full Year 2023 Results 10 jan 2024 22:30

DanCann Pharma A/S Completes Issuance (8) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2 20 dec 2023 09:00

DanCann Pharma A/S delivers annual shareholder letter and investor update 30 nov 2023 18:10

DanCann Pharma A/S: Flagging announcement 30 nov 2023 18:00

DanCann Pharma A/S publishes Q3-2023 report 28 nov 2023 22:00

DanCann Pharma A/S Completes Issuance (7) of New Shares under the Loan-Agreement with Nordic Growth Opportunities 2 - Marking a Milestone with a Conversion Rate Exceeding 50 percent of Tranche 1 22 nov 2023 21:30

DanCann Pharma A/S Completes Issuance (6) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2 26 okt 2023 17:30

DanCann Pharma A/S: Future strategic direction 04 okt 2023 08:00

DanCann Pharma A/S Completes Issuance (5) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2 02 okt 2023 13:00

DanCann Pharma A/S aims to accelerate business and revenue growth: Comprehensive strategy update to follow in October 26 sep 2023 08:45

DanCann Pharma A/S Completes Issuance (4) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2 31 aug 2023 21:00

DanCann Pharma A/S Completes Issuance (3) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2 31 aug 2023 17:30

DanCann Pharma A/S publishes Q2-2023 report 31 aug 2023 08:30

DanCann Pharma A/S to refocus its strategy - will reinvigorate its pipeline and product portfolio, and start looking for future owner or partnership for BP1 18 aug 2023 20:00

Correction: DanCann Pharma A/S Completes Issuance (2) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2 18 aug 2023 18:00

DanCann Pharma A/S Completes Issuance (2) of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2 27 jul 2023 23:00

DanCann Pharma A/S Completes Issuance of New Shares from Debt Conversion under the 10-Year Financing Loan-Agreement with 12-months Conversion Option with Nordic Growth Opportunities 2 17 jul 2023 18:00

DanCann Pharma A/S Successfully Receives First Tranche from the 10-Year Financing Loan-Agreement with 12-months Conversion Option and Warrants with Nordic Growth Opportunities 2 20 jun 2023 12:50

DanCann Pharma A/S: MINUTES OF EXTRAORDINARY GENERAL MEETING 02 jun 2023 18:00

DanCann Pharma A/S: NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S 02 jun 2023 17:20

DanCann Pharma A/S Secures 10-Year Financing Loan-Agreement with 12-months Conversion Option and Warrants 02 jun 2023 17:15

DanCann Pharma receives approximately DKK 5.6 million from the exercise of series TO 2 together with a directed issue to the underwriters 01 jun 2023 09:00

DanCann Pharma A/S' Pre-Validation Batches Meets European Standards, paving the Path for Final Product Approval 31 maj 2023 18:00

DanCann Pharma A/S publishes Q1-2023 report 30 maj 2023 12:00

DanCann Pharma A/S: MINUTES OF ANNUAL GENERAL MEETING 26 maj 2023 08:30

DanCann Pharma A/S has secured 71 percent of the TO 2’s 26 maj 2023 08:15

DanCann Pharma A/S has successfully completed pre-validation batches and expects final approval from the Danish Medicines Agency by the end of summer 26 maj 2023 08:00

DanCann Pharma A/S in advanced talks with new investor of additional DKK 12 million for topping up the outcome of the TO 2’s 24 maj 2023 09:42

Correction: DanCann Pharma A/S invites to an investor presentation and Q&A session in relation to ongoing exercise period of warrants 24 maj 2023 09:00

DanCann Pharma A/S invites to an investor presentation and Q&A session in relation to ongoing exercise period of warrants 16 maj 2023 09:00

DanCann Pharma A/S: The exercise period for warrants of series TO 2 begins today 15 maj 2023 17:00

DanCann Pharma A/S: The subscription price for warrants of series TO 2 has been set 12 maj 2023 09:05

DanCann Pharma A/S is strengthening its regulatory focus by appointing a life science lawyer to the board of directors 12 maj 2023 08:50

NOTICE OF ANNUAL GENERAL MEETING 2023 IN DANCANN PHARMA A/S 12 maj 2023 08:45

DanCann Pharma A/S publishes Annual Report 2022